Related Experiment Video
Updated: Apr 19, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
21.2K
Interleukin-6: a new therapeutic target in systemic sclerosis?
Steven O'Reilly1, Rachel Cant1, Marzena Ciechomska1
1Musculoskeletal Research Group, Institute of Cellular Medicine , Newcastle upon Tyne, UK.
Clinical & Translational Immunology
|December 16, 2014
Summary
Interleukin-6 (IL-6) drives fibrosis in systemic sclerosis (SSc). Targeting IL-6 offers a promising therapeutic strategy for this chronic autoimmune fibrotic disease.
Area of Science:
- Immunology
- Rheumatology
- Pathophysiology
Background:
- Interleukin-6 (IL-6) is a pro-inflammatory cytokine crucial for immune responses.
- IL-6 signaling is typically restricted, but trans-signaling expands its cellular targets.
- IL-6 plays a role in rheumatoid arthritis, Castleman's disease, and Crohn's disease.
Purpose of the Study:
- To review the role of IL-6 in systemic sclerosis (SSc), a fibrotic autoimmune disease.
- To examine the evidence linking IL-6 to fibrosis in SSc.
- To explore downstream effector pathways and therapeutic potential.
Main Methods:
- Literature review focusing on IL-6 and SSc.
- Analysis of evidence for IL-6's role in SSc pathogenesis and fibrosis.
- Examination of IL-6's downstream signaling pathways.
Main Results:
- Elevated IL-6 levels correlate with skin thickness in SSc patients.
- IL-6 has demonstrated direct fibrotic effects.
- IL-6 is implicated in the pathogenesis of SSc.
Conclusions:
- IL-6 is a key mediator of fibrosis in systemic sclerosis.
- Molecular targeting of IL-6 presents a promising therapeutic avenue for SSc.
Related Concept Videos
01:24T Cell Types and Functions
3.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.5K
01:20The JAK-STAT Signaling Pathway
14.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
14.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
824
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
824
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
738
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
738